Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system
暂无分享,去创建一个
C. James | J. Sarkaria | A. Linninger | C. Horbinski | S. Mirkov | R. Lukas | Grant Hartung | K. Tangen | Benjamin P Liu | D. Unruh | C. D. James | Grant A Hartung | Benjamin P Liu
[1] Steven J. M. Jones,et al. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1 , 2017, Proceedings of the National Academy of Sciences.
[2] J. Golfinos,et al. Mutant IDH1 and seizures in patients with glioma , 2017, Neurology.
[3] A. M. Houghton,et al. Mutant IDH1 regulates the tumor-associated immune system in gliomas , 2017, Genes & development.
[4] J. Costello,et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas , 2017, The Journal of clinical investigation.
[5] M. Gilbert,et al. Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair. , 2017, Cancer research.
[6] Gregory A. Breuer,et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity , 2017, Science Translational Medicine.
[7] E. Maher,et al. Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] D. Kondziolka,et al. Mutant IDH1 and thrombosis in gliomas , 2016, Acta Neuropathologica.
[9] Erwin G. Van Meir,et al. Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase , 2016, Clinical Cancer Research.
[10] Andrei I Holodny,et al. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. , 2016, Neuro-oncology.
[11] B. Rosen,et al. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate , 2015, Clinical Cancer Research.
[12] V. Rangnekar,et al. The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells , 2014, Acta Neuropathologica.
[13] K. Ross,et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer , 2014, Nature.
[14] K. Yen,et al. Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. , 2014, The oncologist.
[15] Claude Preudhomme,et al. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Janna H. Neltner,et al. Autophagy and oxidative stress in gliomas with IDH1 mutations , 2014, Acta Neuropathologica.
[17] Jeffrey W. Clark,et al. Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma , 2014, Clinical Cancer Research.
[18] Daniel B Vigneron,et al. Non-invasive in vivo assessment of IDH1 mutational status in glioma , 2013, Nature Communications.
[19] M. Ross,et al. Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2 , 2013, Nature Communications.
[20] Benjamin L. Ebert,et al. (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible , 2013, Science.
[21] C. Horbinski. What do we know about IDH1/2 mutations so far, and how do we use it? , 2013, Acta Neuropathologica.
[22] O. Abdel-Wahab,et al. The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization* , 2012, The Journal of Biological Chemistry.
[23] A. Iafrate,et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. , 2012, Blood.
[24] D. Margolis,et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. , 2012, Blood.
[25] A. Krämer,et al. Enzymatic assay for quantitative analysis of (d)-2-hydroxyglutarate , 2012, Acta Neuropathologica.
[26] S. Inoue,et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. , 2012, Genes & development.
[27] R. Verhaak,et al. Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation , 2012, Nature.
[28] S. Berger,et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.
[29] S. Weiss,et al. An in vivo patient-derived model of endogenous IDH1-mutant glioma. , 2012, Neuro-oncology.
[30] Mitchel S. Berger,et al. Magnetic Resonance of 2-Hydroxyglutarate in IDH1-Mutated Low-Grade Gliomas , 2012, Science Translational Medicine.
[31] A. Grigoriadis,et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.
[32] K. Kinzler,et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome , 2011, Proceedings of the National Academy of Sciences.
[33] A. von Deimling,et al. Increased levels of 2‐hydroxyglutarate in AML patients with IDH1‐R132H and IDH2‐R140Q mutations , 2010, European journal of haematology.
[34] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[35] R. McLendon,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[36] Ken Chen,et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.
[37] U. Del Monte. Does the cell number 109 still really fit one gram of tumor tissue? , 2009, Cell cycle.
[38] M. Wajner,et al. Mitochondrial energy metabolism is markedly impaired by D-2-hydroxyglutaric acid in rat tissues. , 2005, Molecular genetics and metabolism.
[39] M. Wajner,et al. D‐2‐hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats , 2003, The European journal of neuroscience.
[40] Jeffrey W. Clark,et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. , 2012, The oncologist.
[41] M. Roizen,et al. Hallmarks of Cancer: The Next Generation , 2012 .
[42] J. Uhm. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .